BioMarin Pharmaceutical

BMRNNASDAQ

Enzyme replacement and gene therapy

Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-04-09. Published by ClinicalInvestor. Educational analysis only. Read the editorial policy and disclosures.

text updated 2026-04-09, 222 days ago · archived: kept for reference, not maintained · where each field comes from

Key figures from SEC filings

We have not parsed a 10-Q or 10-K for BMRN yet, so this page shows no cash, burn or runway figure rather than an estimate. Revenue stage: Commercial.

Upcoming catalysts

Company-specific dates below are registry milestones or filings we have linked. For FDA decision dates site-wide, see the PDUFA calendar.

No upcoming catalyst for BioMarin Pharmaceutical has been confirmed against a primary source. Rather than estimate one, this section is left empty — check the company's investor relations page and ClinicalTrials.gov directly.

Pipeline

DrugIndicationPhaseExpected data
VoxzogoAchondroplasiaApprovedNot disclosed▼
RoctavianHemophilia AApprovedNot disclosed▼
BMN 349Complement-mediated diseasesPhase 1Not disclosed▼

What does BioMarin Pharmaceutical do?

BioMarin is a well-established rare disease company that has successfully transitioned to commercial profitability. Their flagship product Voxzogo treats achondroplasia with strong uptake worldwide. Their gene therapy Roctavian for hemophilia A received FDA approval but adoption has been slower than expected. The company generates meaningful revenue and is cash flow positive. For investors BMRN represents a lower-risk biotech with real revenue growth though the stock price reflects much of the near-term opportunity. Key questions are whether Voxzogo reaches peak sales and whether Roctavian adoption accelerates.

What to watch

1

Quarterly Voxzogo revenue growth trajectory

2

Roctavian treatment center expansion and uptake

3

BMN 349 Phase 1 safety and PK data

4

Competitive readouts from Ascendis Pharma

5

Operating margin expansion as products mature

Investment thesis

Moderate Risk

Bull case

BioMarin has transformed into a profitable rare disease leader with Voxzogo on a strong growth trajectory and peak sales estimates of $2-3B globally. Deep expertise in rare diseases with multiple approved products generating recurring revenue. Pipeline expanding beyond enzyme replacement into gene therapy and small molecules. Strong cash flow with no near-term dilution risk offers rare disease growth with commercial-stage stability.

Bear case

Roctavian uptake disappointing and may never reach peak sales estimates. Voxzogo faces potential competition from Ascendis Pharma TransCon CNP. Rare disease market inherently limited in size. Gene therapy manufacturing remains complex and expensive. Pipeline complement diversification is very early stage with high clinical risk.

Risk factors

⚠

Roctavian commercial adoption below expectations

⚠

Voxzogo competitive threats from next-gen therapies

⚠

Gene therapy manufacturing complexity

⚠

Rare disease market size limitations

⚠

Regulatory risk for gene therapy label expansions

Trade BMRN commission-free on Webullvia Webull · Affiliate

Comparable companies

ALXNRAREARGXSGEN

Sponsored

Get premium BMRN analysis on Seeking Alpha

Affiliate link — we may earn a commission at no cost to you

Disclaimer: This page is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Clinical trial analysis reflects publicly available data and AI-generated interpretations. Biotech investing carries significant risk including potential total loss of investment. Always verify critical claims through primary sources and consult a qualified financial advisor. Some links on this page are affiliate links. Review our editorial policy and disclosures.

Sponsor's late-stage trial record

BioMarin Pharmaceutical has 70 Phase 2 or 3 studies on ClinicalTrials.gov: 41 completed, 13 stopped early, 16 ongoing.

41

Completed

13

Stopped early

16

Ongoing

Stopped early

  • GENEr8-AAV5+Phase 1/2 · started 2018 · terminated

    Valoctocogene Roxaparvovec in hemophilia a · n=3

    Reason given: Early rollover into long-term extension study

  • NCT02958202Phase 2 · started 2016 · terminated

    BMN 044 IV 6 mg/kg in duchenne muscular dystrophy · n=7

    Reason given: Regulatory approval was not obtained for drisapersen, hence BioMarin is stopping the development of all exon skipping oligonucleotides in DMD.

  • NCT02329769Phase 2 · started 2014 · terminated

    PRO044 SC 6 mg/kg in duchenne muscular dystrophy · n=15

    No reason recorded in the registry.

  • NCT01924845Phase 3 · started 2014 · terminated

    BMN 701 in late-onset pompe disease · n=24

    Reason given: Sponsor decision

  • SIGNALPhase 2 · started 2014 · terminated

    Sapropterin in phenylketonuria · n=2

    Reason given: Recruitment challenges

  • NCT01957059Phase 1/2 · started 2013 · terminated

    Regimen Selection Phase Group 2 in duchenne muscular dystrophy · n=9

    No reason recorded in the registry.

  • NCT01803412Phase 3 · started 2013 · terminated

    Drisapersen in muscular dystrophies · n=53

    No reason recorded in the registry.

  • NCT01826474Phase 1/2 · started 2013 · terminated

    PRO045, 0.15 mg/kg/week in duchenne muscular dystrophy · n=15

    No reason recorded in the registry.

  • NCT01697319Phase 2 · started 2012 · terminated

    BMN 110 in mucopolysaccharidosis iva · n=16

    No reason recorded in the registry.

  • NCT01609062Phase 2 · started 2012 · terminated

    BMN 110 in mucopolysaccharidosis iva · n=25

    No reason recorded in the registry.

  • NCT01435772Phase 2 · started 2011 · terminated

    BMN 701 in pompe disease · n=21

    Reason given: The study was terminated because BioMarin decided to end the overall development program based on competing corporate priorities.

  • NCT01242111Phase 1/2 · started 2010 · terminated

    BMN 110 in mps iv a · n=20

    No reason recorded in the registry.

  • NCT01910649Phase 2 · started 2008 · terminated

    Drisapersen in muscular dystrophies · n=12

    Reason given: Regulatory approval was not obtained for drisapersen, hence BioMarin is stopping the development of all exon skipping oligonucleotides in DMD.

Counts cover interventional Phase 2 and Phase 3 studies registered under this sponsor name, retrieved 2026-09-28 from ClinicalTrials.gov API v2. Trials stop for many reasons — futility, safety, enrollment, funding, or a decision to back a different programme — and the registry often does not say which. This is the sponsor's record, not a prediction about any specific readout.